Trial Outcomes & Findings for Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS (NCT NCT00887679)

NCT ID: NCT00887679

Last Updated: 2014-10-31

Results Overview

The HAM-A is administered by an interviewer who asks a series of questions related to symptoms of anxiety. The interviewer then rates the individual on a five-point scale for each of the 14 items. Seven of the items specifically address psychic anxiety and the remaining seven items address somatic anxiety. The total anxiety score ranges from 0 to 56, lower scores are better. Change from randomization to end of treatment in scores on the Hamilton Anxiety Rating Scale (HAM-A)is measured.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

30 participants

Primary outcome timeframe

baseline and 7 weeks

Results posted on

2014-10-31

Participant Flow

Anxiety disorders in HIV-infected patients from the general population

Participant milestones

Participant milestones
Measure
Escitalopram
Treatment effects of Escitalopram in Generalized Anxiety Disorder in patients with HIV/AIDS.
Overall Study
STARTED
30
Overall Study
COMPLETED
20
Overall Study
NOT COMPLETED
10

Reasons for withdrawal

Reasons for withdrawal
Measure
Escitalopram
Treatment effects of Escitalopram in Generalized Anxiety Disorder in patients with HIV/AIDS.
Overall Study
Withdrawal by Subject
1
Overall Study
Lost to Follow-up
4
Overall Study
Physician Decision
5

Baseline Characteristics

Treatment Effects of Escitalopram (Lexapro®) on Generalized Anxiety Disorder in Patients With HIV and AIDS

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Escitalopram
n=30 Participants
Treatment effects of Escitalopram in Generalized Anxiety Disorder in patients with HIV/AIDS.
Age, Categorical
<=18 years
0 Participants
n=99 Participants
Age, Categorical
Between 18 and 65 years
30 Participants
n=99 Participants
Age, Categorical
>=65 years
0 Participants
n=99 Participants
Age, Continuous
43.6 years
STANDARD_DEVIATION 8.12 • n=99 Participants
Sex: Female, Male
Female
10 Participants
n=99 Participants
Sex: Female, Male
Male
20 Participants
n=99 Participants
Region of Enrollment
United States
30 participants
n=99 Participants

PRIMARY outcome

Timeframe: baseline and 7 weeks

Population: 3 patients dropped out, 4 patients did not met the criteria, and 3 patients did not show up.

The HAM-A is administered by an interviewer who asks a series of questions related to symptoms of anxiety. The interviewer then rates the individual on a five-point scale for each of the 14 items. Seven of the items specifically address psychic anxiety and the remaining seven items address somatic anxiety. The total anxiety score ranges from 0 to 56, lower scores are better. Change from randomization to end of treatment in scores on the Hamilton Anxiety Rating Scale (HAM-A)is measured.

Outcome measures

Outcome measures
Measure
Escitalopram
n=20 Participants
Treatment effects of Escitalopram in Generalized Anxiety Disorder in patients with HIV/AIDS.Subjects received escitalopram 10-20mg. Escitalopram was started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day.
Change From Randomization to End of Treatment in Scores on the Hamilton Anxiety Rating Scale (HAM-A)
21.23 scores on an anxiety scale
Standard Deviation 2.57

PRIMARY outcome

Timeframe: baseline and 7 weeks

Scoring The BDI consist of twenty-one questions about how the subject has been feeling in the last week. Each question has a set of at least four possible answer choices, ranging in intensity as follows: (0) I do not feel sad. 1. I feel sad. 2. I am sad all the time and I can't snap out of it. 3. I am so sad or unhappy that I can't stand it. A value of 0 to 3 is assigned for each answer and the total score is compared to a key to determine the depression's severity. The standard cut-offs are as follows:\[6\] 0-9: indicates minimal depression 10-18: indicates mild depression 19-29: indicates moderate depression 30-63: indicates severe depression. Higher total scores indicate more severe depressive symptoms.

Outcome measures

Outcome measures
Measure
Escitalopram
n=20 Participants
Treatment effects of Escitalopram in Generalized Anxiety Disorder in patients with HIV/AIDS.Subjects received escitalopram 10-20mg. Escitalopram was started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day.
Changes From Randomization to End of Treatment in Scores on the Beck Depression Inventory
27.8 units on a scale
Standard Deviation 7.89

SECONDARY outcome

Timeframe: baseline and 7 weeks

Population: 3 patients dropped out, 4 patients did not meet criteria, and 3 patients did not show up.

Scale for scoring: Clinical Global Impression(CGI-S) 1. = Normal, no symptoms 2. = Borderline ill 3. = Mildly ill 4. = Moderately ill 5. = Markedly ill 6. = Severely ill 7. = Most extremely ill Clinical Global Impression(CGI-I)-improvement since treatment 1. very much improved 2. much improved 3. minimally improved 4. no change from baseline 5. minimally worse 6. much worse 7. very much worse

Outcome measures

Outcome measures
Measure
Escitalopram
n=20 Participants
Treatment effects of Escitalopram in Generalized Anxiety Disorder in patients with HIV/AIDS.Subjects received escitalopram 10-20mg. Escitalopram was started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day.
Change From Randomization to End of Treatment in Scores for the Clinical Global Impression(CGI-S and CGI-I)
Clinical Global Impression (CGI-I)
1 scores on a scale
Standard Deviation 0.0
Change From Randomization to End of Treatment in Scores for the Clinical Global Impression(CGI-S and CGI-I)
Clinical Global Impression (CGI-S)
2 scores on a scale
Standard Deviation 1.0

SECONDARY outcome

Timeframe: baseline to 7 weeks

Trail Making Test (TMT)Results for TMT are reported as the number of seconds required to complete the task. Higher scores reveal greater impairment. Average =29 seconds, Deficient \> 78 seconds

Outcome measures

Outcome measures
Measure
Escitalopram
n=20 Participants
Treatment effects of Escitalopram in Generalized Anxiety Disorder in patients with HIV/AIDS.Subjects received escitalopram 10-20mg. Escitalopram was started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day.
Change From Randomization to End of Treatment for Trail Making Tet (TMT)
29.2 seconds
Standard Deviation 11.23

SECONDARY outcome

Timeframe: baseline and 7 weeks

Mini Mental State Examination (MMSE),a low score less than or equal to 23 indicates cognitive impairment and the need for further evaluation; normal cognitive function = 27-30, mild cognitive impairment = 21-26, moderate cognitive impairment = 11-20, and severe cognitive impairment = 0-10. The highest possible score is 30.

Outcome measures

Outcome measures
Measure
Escitalopram
n=20 Participants
Treatment effects of Escitalopram in Generalized Anxiety Disorder in patients with HIV/AIDS.Subjects received escitalopram 10-20mg. Escitalopram was started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day.
Changes From Randomization to End of Treatment in Scores on the Mini Mental State Examination (MMSE)
0 units on a scale
Standard Deviation 0

SECONDARY outcome

Timeframe: baseline and 7 weeks

Scoring: Participants rate the extent to which work, social life, and home life are impaired by his or her symptoms. A 10 point scale is used where 0= not impaired and 10 is highly impaired indicating. The three aspects of life can be summed up into a single dimensional measure of global functional impairment that indicates 0= not impaired and 30 = highly impaired. Scores of 5 or greater are on any of the three scales are considered significant.

Outcome measures

Outcome measures
Measure
Escitalopram
n=20 Participants
Treatment effects of Escitalopram in Generalized Anxiety Disorder in patients with HIV/AIDS.Subjects received escitalopram 10-20mg. Escitalopram was started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day.
Changes From Randomization to End of Treatment in Scores on the Sheehan Disability Scores (SDS)
0 units on a scale
Standard Deviation 0

Adverse Events

Escitalopram

Serious events: 0 serious events
Other events: 21 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Escitalopram
n=30 participants at risk
Treatment effects of Escitalopram in Generalized Anxiety Disorder in patients with HIV/AIDS.
Gastrointestinal disorders
nause
23.3%
7/30
Nervous system disorders
dizziness
13.3%
4/30
Gastrointestinal disorders
diarrhea
10.0%
3/30
Gastrointestinal disorders
dry mouth
13.3%
4/30
Nervous system disorders
headache
3.3%
1/30
Gastrointestinal disorders
constipation
6.7%
2/30

Additional Information

Dr. Ashwin A Patkar Associate Professor

Duke University Medical Center

Phone: 919-668-3626

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place